Equity Profile

CTMX

CytomX Therapeutics, Inc.

Health CareBiotechnology$734.3M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS gives insight into the company's profitability and operational efficiency, which is crucial for investor confidence.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's market acceptance and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $1 billion, it operates in the healthcare sector, aiming to create treatments that target specific cancer cells while minimizing damage to healthy tissue.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, which was better than the expected -$0.14, indicating a positive surprise. However, the stock fell by 3.15% the following day, reflecting market skepticism despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the mixed performance in previous quarters and lack of strong guidance from management.

Bull Case

If CytomX can demonstrate significant progress in its drug pipeline or better-than-expected revenue, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company fails to show progress or reports disappointing metrics, it could trigger further declines in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the drug pipeline are crucial as they can significantly influence investor sentiment and the stock price.

How does management plan to address the recent volatility in stock performance?

Understanding management's strategy to stabilize the stock and improve investor confidence will be key for market reactions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of upcoming clinical trial results, which could significantly shift market sentiment.

Supporting Evidence

The options market indicates a high level of expected volatility, suggesting that traders are anticipating major news.

CytomX has a history of surprising the market with better-than-expected results, which could happen again.

The recent stock price movements suggest that investors are not fully pricing in the potential upside from successful trial outcomes.

Key Risk

If the drug pipeline shows unexpected positive results, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter hinges on the company's ability to showcase progress in its drug development efforts amidst a backdrop of mixed past performance.

Bull Confirmed If

Demonstrating a significant advancement in clinical trials or a notable partnership could confirm the bull case.

Bear Confirmed If

Failure to provide clarity on the drug pipeline or disappointing results could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant move of 37.5%, suggesting that traders expect a volatile reaction to the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests a potential stock increase of around 25.20%, confirming a positive outlook.

In-Line / Cautious

An in-line report with cautious commentary could lead to muted reactions, reflecting ongoing investor uncertainty.

Miss

If the company misses expectations, history suggests a decline of around 15.16%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new partnerships.
2Management's commentary on addressing stock volatility.
3Insights into revenue generation strategies and market expansion plans.
4Any changes in guidance or outlook for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS gives insight into the company's profitability and operational efficiency, which is crucial for investor confidence.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's market acceptance and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the mixed performance in previous quarters and lack of strong guidance from management.

Bull Case

If CytomX can demonstrate significant progress in its drug pipeline or better-than-expected revenue, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company fails to show progress or reports disappointing metrics, it could trigger further declines in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the drug pipeline are crucial as they can significantly influence investor sentiment and the stock price.

How does management plan to address the recent volatility in stock performance?

Understanding management's strategy to stabilize the stock and improve investor confidence will be key for market reactions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of upcoming clinical trial results, which could significantly shift market sentiment.

Supporting Evidence

The options market indicates a high level of expected volatility, suggesting that traders are anticipating major news.

CytomX has a history of surprising the market with better-than-expected results, which could happen again.

The recent stock price movements suggest that investors are not fully pricing in the potential upside from successful trial outcomes.

Key Risk

If the drug pipeline shows unexpected positive results, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter hinges on the company's ability to showcase progress in its drug development efforts amidst a backdrop of mixed past performance.

Bull Confirmed If

Demonstrating a significant advancement in clinical trials or a notable partnership could confirm the bull case.

Bear Confirmed If

Failure to provide clarity on the drug pipeline or disappointing results could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant move of 37.5%, suggesting that traders expect a volatile reaction to the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests a potential stock increase of around 25.20%, confirming a positive outlook.

In-Line / Cautious

An in-line report with cautious commentary could lead to muted reactions, reflecting ongoing investor uncertainty.

Miss

If the company misses expectations, history suggests a decline of around 15.16%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new partnerships.
2Management's commentary on addressing stock volatility.
3Insights into revenue generation strategies and market expansion plans.
4Any changes in guidance or outlook for the upcoming quarters.